Michael Rosenblum, MD
Cardiovascular Disease · Murrells Inlet, SCNPI 1700084431
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $25,250 of the $38,737 with a category attached, or 65.2%. 29 manufacturers reported payments, led by Pfizer at 42.3% of the total. 2025 is the largest year on record at $12,325, 9.9 times the $1,241 reported in 2019. Among cardiovascular disease clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 296 payments — averaging $130.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$16K
- Boston Scientific$8K
- Heartflow, Inc.$5K
- Abbott$4K
- Medtronic$2K
- Amgen$450
- plus $3K from 23 others
What the payments were for
- Consulting fees$3,0008%
- Speaking & faculty fees$25,25065%
- Travel & lodging$1,8035%
- Food & beverage$8,66522%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 30 | $16,401 |
| Boston Scientific | 21 | $7,581 |
| Heartflow, Inc. | 15 | $5,230 |
| Abbott | 44 | $4,389 |
| Medtronic | 28 | $1,569 |
| Amgen | 22 | $450 |
| Novartis | 32 | $439 |
| Cvrx, Inc. | 8 | $418 |
| Siemens Medical Solutions USA, Inc. | 3 | $356 |
| Alnylam Pharmaceuticals Inc. | 10 | $217 |
| AstraZeneca | 13 | $198 |
| Johnson & Johnson | 12 | $187 |
| E.r. Squibb & Sons, L.L.C. | 10 | $186 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $127 |
| Cardiva Medical, Inc. | 2 | $117 |
| Amarin Pharma, Inc. | 6 | $111 |
| GE HealthCare | 2 | $110 |
| Scpharmaceuticals Inc. | 4 | $105 |
| Edwards Lifesciences | 3 | $89 |
| Atricure, Inc. | 2 | $74 |
| Baxter Healthcare | 4 | $72 |
| Novo Nordisk | 2 | $60 |
| Merck | 3 | $51 |
| Irhythm Technologies, Inc. | 2 | $43 |
| Astellas Pharma US Inc | 3 | $42 |
| Boehringer Ingelheim | 3 | $40 |
| Preventice Services, LLC | 1 | $40 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Cleerly, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$12,400
- WATCHMAN Access System$6,098
- FFRct$4,999
- AMPLATZER AMULET$3,000
- WATCHMAN FLX$1,186
- COBALT DR MRI SURESCAN$602
- MAGNETOM Sola$284
- Barostim Neo System$208
- Micra$171
- AVEIR$111
How this compares
$38,737 in reported general payments places this provider in the 95th percentile of 257 cardiovascular disease providers in South Carolina.
See all cardiovascular disease providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 575 | $618,331 |
| EntrestoSacubitril/Valsartan | 188 | $216,637 |
| XareltoRivaroxaban | 114 | $123,897 |
| FarxigaDapagliflozin Propanediol | 102 | $91,839 |
| Repatha SureclickEvolocumab | 59 | $55,797 |
| MultaqDronedarone Hcl | 44 | $40,022 |
| JardianceEmpagliflozin | 18 | $19,923 |
| VascepaIcosapent Ethyl | 22 | $15,711 |
| Praluent PenAlirocumab | 23 | $15,328 |
| Metoprolol Succinate | 825 | $14,499 |
| Repatha PushtronexEvolocumab | 14 | $12,836 |
| Rosuvastatin Calcium | 380 | $6,380 |
| Irbesartan | 259 | $5,989 |
| Bumetanide | 147 | $4,295 |
| Pravastatin Sodium | 282 | $3,796 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $16,401 | $618,331575 claims |
| NovartisEntresto | $439 | $216,637188 claims |
| Johnson & JohnsonXarelto | $187 | $123,897114 claims |
| AstraZenecaFarxiga | $198 | $91,839102 claims |
| Sanofi-aventis U.S. LLCMultaq | $20 | $40,02244 claims |
| Boehringer IngelheimJardiance | $40 | $19,92318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 257 cardiovascular disease providers in South Carolina.
Other cardiovascular disease in Murrells Inlet
- Robert BiedermanCharleston$775K
- Darren SidneyNorth Charleston$129K
- Priyanka BhattacharyaCharleston$107K
- Gregory SanGreenville$88K
- David McNeelyGreenville$78K
- Gregory EavesAiken$65K
- James SmithCharleston$64K
- Christopher SalmonGreenville$54K
- Ricky HendersonAnderson$52K
- Geetha PintoCharleston$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.